LUMAKRAS™ now available from Onco360!
LUMAKRAS™ (sotorasib) is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
Dosage and Administration 1
The recommended dose for LUMAKRAS is 960 mg (eight 120 mg tablets) orally once daily.
Dosage Forms and Strengths
LUMAKRAS is available in 120 mg tablets.
- Carton containing two bottles of 120 tablets (NDC 55513-488-02)
- Carton containing one bottle of 240 tablets (NDC 55513-488-24)
For more information, visit LUMAKRAS.com
How to Refer
Oncomed Dba Onco360 or
1LUMAKRAS™ Prescribing Information: Amgen, Inc. accessed 6/2021. LUMAKRAS™ trademark is owned or licensed by Amgen, Inc.